| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 72 | 2020 | 192 | 11.870 |
Why?
|
| Kidney Neoplasms | 54 | 2021 | 201 | 10.230 |
Why?
|
| Carcinoma, Renal Cell | 34 | 2021 | 114 | 7.600 |
Why?
|
| Cystectomy | 49 | 2020 | 105 | 5.960 |
Why?
|
| Carcinoma, Transitional Cell | 28 | 2020 | 69 | 4.840 |
Why?
|
| Neoplasm Recurrence, Local | 30 | 2021 | 367 | 3.930 |
Why?
|
| Prostatic Neoplasms | 48 | 2022 | 471 | 3.650 |
Why?
|
| Nephrectomy | 16 | 2021 | 123 | 2.760 |
Why?
|
| Wilms Tumor | 5 | 2017 | 14 | 2.180 |
Why?
|
| Humans | 200 | 2022 | 32082 | 2.060 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 606 | 2.050 |
Why?
|
| Neoplasm Staging | 35 | 2021 | 447 | 1.880 |
Why?
|
| Prostatic Hyperplasia | 10 | 2016 | 44 | 1.870 |
Why?
|
| beta Catenin | 6 | 2017 | 37 | 1.770 |
Why?
|
| Male | 142 | 2022 | 19202 | 1.710 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 261 | 1.460 |
Why?
|
| Aged | 89 | 2021 | 10308 | 1.440 |
Why?
|
| Middle Aged | 92 | 2021 | 11834 | 1.420 |
Why?
|
| Neoadjuvant Therapy | 13 | 2019 | 67 | 1.400 |
Why?
|
| Prostatectomy | 17 | 2016 | 83 | 1.360 |
Why?
|
| Neoplasm Invasiveness | 23 | 2017 | 190 | 1.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2019 | 458 | 1.270 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 407 | 1.160 |
Why?
|
| Female | 81 | 2021 | 19999 | 1.140 |
Why?
|
| Survival Rate | 23 | 2017 | 876 | 1.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 14 | 1.110 |
Why?
|
| Urinary Bladder | 5 | 2019 | 182 | 1.050 |
Why?
|
| Prognosis | 28 | 2021 | 1496 | 1.000 |
Why?
|
| Aged, 80 and over | 41 | 2019 | 3990 | 0.980 |
Why?
|
| Treatment Outcome | 37 | 2017 | 3304 | 0.950 |
Why?
|
| Urinary Diversion | 9 | 2020 | 26 | 0.920 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 317 | 0.910 |
Why?
|
| Retrospective Studies | 34 | 2021 | 3505 | 0.840 |
Why?
|
| Carcinoma | 4 | 2013 | 91 | 0.830 |
Why?
|
| Receptors, Androgen | 6 | 2020 | 47 | 0.810 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2012 | 190 | 0.800 |
Why?
|
| Prostate | 9 | 2016 | 68 | 0.790 |
Why?
|
| Risk Factors | 31 | 2019 | 3880 | 0.780 |
Why?
|
| Body Mass Index | 4 | 2021 | 923 | 0.780 |
Why?
|
| Disease Progression | 16 | 2018 | 594 | 0.750 |
Why?
|
| Follow-Up Studies | 22 | 2021 | 2263 | 0.740 |
Why?
|
| Catheter Ablation | 5 | 2007 | 67 | 0.740 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 1 | 0.740 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 1020 | 0.730 |
Why?
|
| Infection Control | 1 | 2020 | 28 | 0.720 |
Why?
|
| Patient Care | 1 | 2020 | 30 | 0.720 |
Why?
|
| Administration, Intravesical | 8 | 2015 | 24 | 0.720 |
Why?
|
| Adenocarcinoma | 6 | 2018 | 308 | 0.690 |
Why?
|
| Prostate-Specific Antigen | 13 | 2022 | 62 | 0.680 |
Why?
|
| Penile Neoplasms | 3 | 2014 | 6 | 0.670 |
Why?
|
| Mutation | 5 | 2017 | 485 | 0.660 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2009 | 13 | 0.660 |
Why?
|
| Adult | 36 | 2021 | 9375 | 0.660 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 75 | 0.650 |
Why?
|
| Signal Transduction | 11 | 2017 | 680 | 0.650 |
Why?
|
| Postoperative Complications | 12 | 2020 | 780 | 0.640 |
Why?
|
| DNA, Neoplasm | 3 | 2010 | 55 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 99 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.640 |
Why?
|
| Risk Assessment | 15 | 2021 | 1427 | 0.610 |
Why?
|
| Metabolomics | 1 | 2018 | 54 | 0.590 |
Why?
|
| Pyrvinium Compounds | 1 | 2017 | 1 | 0.590 |
Why?
|
| Anthelmintics | 1 | 2017 | 3 | 0.590 |
Why?
|
| Interferon-alpha | 2 | 2010 | 70 | 0.580 |
Why?
|
| Urethral Neoplasms | 3 | 2009 | 5 | 0.580 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 35 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2018 | 917 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 68 | 0.560 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 55 | 0.550 |
Why?
|
| Doxorubicin | 2 | 2015 | 82 | 0.550 |
Why?
|
| Cohort Studies | 23 | 2021 | 1816 | 0.540 |
Why?
|
| African Americans | 5 | 2021 | 1424 | 0.520 |
Why?
|
| BCG Vaccine | 2 | 2013 | 8 | 0.520 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 104 | 0.520 |
Why?
|
| Lymph Nodes | 3 | 2013 | 107 | 0.510 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 93 | 0.510 |
Why?
|
| E2F1 Transcription Factor | 1 | 2015 | 3 | 0.510 |
Why?
|
| Lymph Node Excision | 9 | 2014 | 89 | 0.510 |
Why?
|
| RNA, Messenger | 2 | 2017 | 507 | 0.510 |
Why?
|
| Muscle Neoplasms | 3 | 2013 | 8 | 0.500 |
Why?
|
| United States | 21 | 2021 | 3975 | 0.490 |
Why?
|
| Asian Americans | 1 | 2015 | 97 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 81 | 0.490 |
Why?
|
| NF-kappa B | 6 | 2016 | 81 | 0.490 |
Why?
|
| Robotics | 6 | 2014 | 124 | 0.480 |
Why?
|
| Laparoscopy | 7 | 2014 | 172 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 835 | 0.480 |
Why?
|
| Mice | 14 | 2021 | 2474 | 0.470 |
Why?
|
| Malnutrition | 2 | 2011 | 17 | 0.470 |
Why?
|
| Obesity | 3 | 2019 | 1176 | 0.470 |
Why?
|
| Immunohistochemistry | 7 | 2020 | 534 | 0.450 |
Why?
|
| Animals | 17 | 2021 | 7510 | 0.440 |
Why?
|
| Urothelium | 5 | 2015 | 55 | 0.440 |
Why?
|
| Neoplasm Metastasis | 10 | 2017 | 220 | 0.440 |
Why?
|
| Inflammation | 2 | 2016 | 529 | 0.430 |
Why?
|
| Urology | 5 | 2018 | 31 | 0.430 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 5 | 2016 | 10 | 0.430 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 145 | 0.420 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 26 | 0.420 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 19 | 0.420 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 753 | 0.420 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 60 | 0.410 |
Why?
|
| Proteome | 1 | 2012 | 39 | 0.410 |
Why?
|
| Kidney | 4 | 2021 | 518 | 0.400 |
Why?
|
| Genes, ras | 1 | 2011 | 26 | 0.400 |
Why?
|
| Carrier Proteins | 3 | 2018 | 136 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 1062 | 0.390 |
Why?
|
| Cell Proliferation | 5 | 2021 | 604 | 0.390 |
Why?
|
| Apoptosis | 3 | 2016 | 353 | 0.380 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2010 | 5 | 0.380 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 725 | 0.370 |
Why?
|
| Carcinoma in Situ | 3 | 2006 | 15 | 0.370 |
Why?
|
| Tennessee | 4 | 2016 | 102 | 0.370 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 23 | 0.360 |
Why?
|
| Nutritional Status | 1 | 2011 | 75 | 0.360 |
Why?
|
| Time Factors | 15 | 2016 | 2145 | 0.360 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 547 | 0.360 |
Why?
|
| Disease Management | 3 | 2020 | 126 | 0.360 |
Why?
|
| Preoperative Care | 2 | 2007 | 114 | 0.340 |
Why?
|
| Prospective Studies | 14 | 2019 | 2282 | 0.340 |
Why?
|
| Cystoscopy | 4 | 2018 | 27 | 0.340 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2009 | 3 | 0.330 |
Why?
|
| Immunotherapy, Active | 1 | 2009 | 6 | 0.330 |
Why?
|
| Survival Analysis | 8 | 2021 | 483 | 0.330 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 24 | 0.320 |
Why?
|
| Neuroectodermal Tumors | 1 | 2008 | 2 | 0.320 |
Why?
|
| Benzamides | 2 | 2020 | 50 | 0.320 |
Why?
|
| Combined Modality Therapy | 7 | 2017 | 560 | 0.310 |
Why?
|
| NFI Transcription Factors | 2 | 2020 | 13 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2015 | 154 | 0.310 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 93 | 0.300 |
Why?
|
| Organ Size | 5 | 2016 | 218 | 0.290 |
Why?
|
| Microwaves | 1 | 2007 | 8 | 0.290 |
Why?
|
| Carotenoids | 2 | 2006 | 10 | 0.290 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 37 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 67 | 0.290 |
Why?
|
| Incidence | 9 | 2018 | 1199 | 0.290 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 53 | 0.280 |
Why?
|
| Exercise | 1 | 2012 | 672 | 0.280 |
Why?
|
| Brachytherapy | 4 | 2008 | 24 | 0.280 |
Why?
|
| Age Factors | 4 | 2008 | 1187 | 0.270 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2016 | 4 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2005 | 20 | 0.270 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 25 | 0.270 |
Why?
|
| Myofibroma | 1 | 2005 | 1 | 0.260 |
Why?
|
| Societies, Medical | 4 | 2018 | 164 | 0.260 |
Why?
|
| Angiomyolipoma | 3 | 2004 | 6 | 0.260 |
Why?
|
| Myelolipoma | 1 | 2005 | 1 | 0.250 |
Why?
|
| Flow Cytometry | 1 | 2005 | 185 | 0.250 |
Why?
|
| Estramustine | 2 | 2003 | 2 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 42 | 0.240 |
Why?
|
| Quality of Life | 4 | 2014 | 946 | 0.240 |
Why?
|
| Sex Factors | 4 | 2021 | 667 | 0.240 |
Why?
|
| Databases, Factual | 4 | 2011 | 354 | 0.240 |
Why?
|
| Hysteroscopy | 1 | 2004 | 4 | 0.240 |
Why?
|
| Blood Loss, Surgical | 4 | 2013 | 49 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2017 | 57 | 0.240 |
Why?
|
| Urologic Neoplasms | 1 | 2004 | 14 | 0.230 |
Why?
|
| Thalidomide | 1 | 2004 | 31 | 0.230 |
Why?
|
| Germ Cells | 2 | 2022 | 10 | 0.230 |
Why?
|
| Laser Therapy | 1 | 2004 | 55 | 0.230 |
Why?
|
| Lymphatic Metastasis | 6 | 2014 | 166 | 0.230 |
Why?
|
| Up-Regulation | 4 | 2020 | 189 | 0.230 |
Why?
|
| Diagnostic Techniques, Urological | 2 | 2014 | 4 | 0.230 |
Why?
|
| Case-Control Studies | 9 | 2022 | 895 | 0.220 |
Why?
|
| Oxidative Stress | 2 | 2016 | 229 | 0.220 |
Why?
|
| Trinucleotide Repeats | 1 | 2003 | 9 | 0.220 |
Why?
|
| Patient Readmission | 3 | 2014 | 126 | 0.210 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 765 | 0.210 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 873 | 0.200 |
Why?
|
| Urination | 2 | 2012 | 16 | 0.200 |
Why?
|
| Recurrence | 4 | 2013 | 263 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 111 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 169 | 0.200 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2014 | 5 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2014 | 186 | 0.190 |
Why?
|
| Lithotripsy | 1 | 2021 | 11 | 0.190 |
Why?
|
| Etoposide | 1 | 2001 | 34 | 0.190 |
Why?
|
| Urolithiasis | 1 | 2021 | 7 | 0.190 |
Why?
|
| Urban Health | 1 | 2021 | 15 | 0.190 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 7 | 0.190 |
Why?
|
| Patient Care Management | 1 | 2021 | 18 | 0.190 |
Why?
|
| Odds Ratio | 3 | 2019 | 472 | 0.190 |
Why?
|
| Nitriles | 1 | 2020 | 23 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2021 | 53 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 37 | 0.180 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 261 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 69 | 0.180 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 322 | 0.180 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 65 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 510 | 0.180 |
Why?
|
| Urologic Surgical Procedures | 1 | 2021 | 64 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 104 | 0.180 |
Why?
|
| Genetic Loci | 2 | 2017 | 146 | 0.180 |
Why?
|
| Androgen Antagonists | 2 | 2010 | 19 | 0.170 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 138 | 0.170 |
Why?
|
| Length of Stay | 7 | 2014 | 312 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2021 | 142 | 0.170 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 178 | 0.170 |
Why?
|
| Logistic Models | 4 | 2015 | 783 | 0.170 |
Why?
|
| Cystitis | 1 | 2018 | 8 | 0.160 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 13 | 0.160 |
Why?
|
| Patient Selection | 4 | 2017 | 276 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 172 | 0.160 |
Why?
|
| Population Dynamics | 1 | 2018 | 6 | 0.160 |
Why?
|
| Protein Kinases | 2 | 2009 | 26 | 0.160 |
Why?
|
| Stents | 1 | 2020 | 177 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2019 | 59 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 94 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2008 | 40 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2009 | 85 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2010 | 58 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2019 | 64 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 100 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 160 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 112 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 232 | 0.150 |
Why?
|
| Telomere | 1 | 2017 | 10 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 9 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 28 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2019 | 185 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 764 | 0.150 |
Why?
|
| Tissue Array Analysis | 4 | 2020 | 34 | 0.140 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2017 | 2 | 0.140 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 581 | 0.140 |
Why?
|
| Cytokines | 2 | 2009 | 256 | 0.140 |
Why?
|
| Genotype | 3 | 2015 | 733 | 0.140 |
Why?
|
| Biopsy | 4 | 2016 | 259 | 0.140 |
Why?
|
| Enzyme Activation | 1 | 2017 | 135 | 0.140 |
Why?
|
| Racemases and Epimerases | 1 | 2016 | 4 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 137 | 0.140 |
Why?
|
| Base Sequence | 1 | 2017 | 252 | 0.140 |
Why?
|
| Gene Expression | 4 | 2020 | 337 | 0.140 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2016 | 1 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2016 | 6 | 0.140 |
Why?
|
| Health Literacy | 1 | 2016 | 30 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2016 | 38 | 0.130 |
Why?
|
| Cell Movement | 1 | 2017 | 169 | 0.130 |
Why?
|
| Pulmonary Emphysema | 1 | 2016 | 21 | 0.130 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2017 | 40 | 0.130 |
Why?
|
| Genes, Wilms Tumor | 1 | 2015 | 6 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2018 | 210 | 0.130 |
Why?
|
| Fibronectins | 1 | 2015 | 36 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2017 | 141 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 23 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 125 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2011 | 311 | 0.130 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 50 | 0.130 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 42 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2015 | 82 | 0.120 |
Why?
|
| Hypoalbuminemia | 1 | 2014 | 11 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2017 | 443 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1325 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 22 | 0.120 |
Why?
|
| PPAR gamma | 2 | 2011 | 46 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 125 | 0.120 |
Why?
|
| Data Collection | 2 | 2011 | 181 | 0.120 |
Why?
|
| Body Composition | 1 | 2016 | 396 | 0.120 |
Why?
|
| Algorithms | 2 | 2018 | 496 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2014 | 19 | 0.120 |
Why?
|
| F2-Isoprostanes | 1 | 2014 | 20 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 145 | 0.120 |
Why?
|
| European Continental Ancestry Group | 2 | 2009 | 1165 | 0.110 |
Why?
|
| Blood Transfusion | 2 | 2013 | 73 | 0.110 |
Why?
|
| Adolescent | 5 | 2018 | 3568 | 0.110 |
Why?
|
| Urethra | 3 | 2016 | 102 | 0.110 |
Why?
|
| ROC Curve | 4 | 2016 | 163 | 0.110 |
Why?
|
| Medical Oncology | 2 | 2011 | 86 | 0.110 |
Why?
|
| Pathology, Molecular | 1 | 2012 | 16 | 0.110 |
Why?
|
| Intestines | 1 | 2012 | 61 | 0.100 |
Why?
|
| Prostatism | 1 | 2012 | 3 | 0.100 |
Why?
|
| Leisure Activities | 1 | 2012 | 14 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 543 | 0.100 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 25 | 0.100 |
Why?
|
| Aging | 2 | 2016 | 943 | 0.100 |
Why?
|
| Workplace | 1 | 2012 | 50 | 0.100 |
Why?
|
| PAX2 Transcription Factor | 1 | 2011 | 2 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Digital Rectal Examination | 2 | 2009 | 10 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 5 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2012 | 134 | 0.100 |
Why?
|
| Proteomics | 1 | 2012 | 93 | 0.100 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 1128 | 0.100 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 47 | 0.100 |
Why?
|
| Methionine | 1 | 2011 | 8 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 512 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 40 | 0.100 |
Why?
|
| Exons | 1 | 2011 | 52 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2011 | 50 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 61 | 0.100 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2011 | 13 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 35 | 0.100 |
Why?
|
| Keratin-20 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2012 | 147 | 0.090 |
Why?
|
| Preoperative Period | 1 | 2011 | 35 | 0.090 |
Why?
|
| Vitamins | 2 | 2009 | 68 | 0.090 |
Why?
|
| Phenotype | 3 | 2017 | 632 | 0.090 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 17 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2011 | 331 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2011 | 54 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2010 | 32 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2010 | 66 | 0.090 |
Why?
|
| General Surgery | 1 | 2011 | 88 | 0.090 |
Why?
|
| Testicular Hydrocele | 1 | 2010 | 1 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 14 | 0.090 |
Why?
|
| Hydronephrosis | 1 | 2010 | 12 | 0.090 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2010 | 7 | 0.090 |
Why?
|
| Mass Screening | 1 | 2012 | 263 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2010 | 30 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 18 | 0.090 |
Why?
|
| Prostatic Diseases | 1 | 2009 | 1 | 0.090 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2009 | 2 | 0.090 |
Why?
|
| Comorbidity | 2 | 2011 | 566 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 21 | 0.090 |
Why?
|
| Area Under Curve | 3 | 2016 | 93 | 0.080 |
Why?
|
| Health Facility Size | 1 | 2009 | 3 | 0.080 |
Why?
|
| Ablation Techniques | 2 | 2021 | 25 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 23 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 516 | 0.080 |
Why?
|
| Surgery Department, Hospital | 1 | 2009 | 7 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2009 | 81 | 0.080 |
Why?
|
| Drug Design | 1 | 2009 | 43 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 58 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 16 | 0.080 |
Why?
|
| Plants, Edible | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 881 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 28 | 0.080 |
Why?
|
| Masculinity | 1 | 2008 | 6 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 1999 | 124 | 0.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2010 | 10 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 34 | 0.080 |
Why?
|
| Hospital Mortality | 4 | 2012 | 198 | 0.080 |
Why?
|
| Urachus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 15 | 0.080 |
Why?
|
| Sigmoid Diseases | 1 | 2008 | 4 | 0.080 |
Why?
|
| Cutaneous Fistula | 1 | 2008 | 4 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 46 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2008 | 9 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2005 | 78 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 684 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 299 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 171 | 0.080 |
Why?
|
| Urination Disorders | 1 | 2007 | 5 | 0.080 |
Why?
|
| Computational Biology | 2 | 2019 | 91 | 0.070 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1542 | 0.070 |
Why?
|
| Anesthesia, Local | 1 | 2007 | 16 | 0.070 |
Why?
|
| Fertility Agents, Female | 1 | 2007 | 8 | 0.070 |
Why?
|
| Leuprolide | 1 | 2007 | 7 | 0.070 |
Why?
|
| Conscious Sedation | 1 | 2007 | 24 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Urethral Stricture | 1 | 2007 | 31 | 0.070 |
Why?
|
| Breast Neoplasms, Male | 1 | 2007 | 11 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 244 | 0.070 |
Why?
|
| I-kappa B Proteins | 2 | 2014 | 10 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 276 | 0.070 |
Why?
|
| Pain Measurement | 3 | 2020 | 349 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 59 | 0.070 |
Why?
|
| Weight Loss | 1 | 2011 | 480 | 0.070 |
Why?
|
| Health Behavior | 1 | 2009 | 236 | 0.070 |
Why?
|
| Contrast Media | 1 | 2007 | 138 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 129 | 0.070 |
Why?
|
| Vinblastine | 1 | 2006 | 6 | 0.070 |
Why?
|
| Prednisone | 1 | 2006 | 61 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 157 | 0.070 |
Why?
|
| Wnt Proteins | 2 | 2017 | 18 | 0.070 |
Why?
|
| Diet | 1 | 2009 | 390 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 77 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 215 | 0.070 |
Why?
|
| Ploidies | 1 | 2005 | 7 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 90 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 989 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 297 | 0.060 |
Why?
|
| DNA Damage | 1 | 2005 | 99 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2006 | 80 | 0.060 |
Why?
|
| Linear Models | 2 | 2010 | 448 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 357 | 0.060 |
Why?
|
| North Carolina | 3 | 2021 | 1538 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 198 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2015 | 41 | 0.060 |
Why?
|
| ADP Ribose Transferases | 1 | 2004 | 4 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2005 | 76 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2005 | 149 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2004 | 18 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 35 | 0.060 |
Why?
|
| Risk | 3 | 2011 | 321 | 0.060 |
Why?
|
| Remission Induction | 1 | 2004 | 84 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2007 | 241 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2665 | 0.060 |
Why?
|
| Fractures, Spontaneous | 1 | 2003 | 16 | 0.060 |
Why?
|
| Diphosphonates | 1 | 2003 | 9 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2004 | 139 | 0.060 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 9 | 0.060 |
Why?
|
| Dihydrotestosterone | 1 | 2003 | 4 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 493 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2020 | 244 | 0.050 |
Why?
|
| Renal Veins | 1 | 2002 | 7 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2016 | 181 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2002 | 30 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 1999 | 88 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 184 | 0.050 |
Why?
|
| Bone Density | 1 | 2003 | 205 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2007 | 101 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 51 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 27 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2015 | 469 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 32 | 0.050 |
Why?
|
| Counseling | 1 | 2021 | 97 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 110 | 0.050 |
Why?
|
| Anastomosis, Surgical | 2 | 2012 | 58 | 0.050 |
Why?
|
| Transfection | 1 | 2020 | 190 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 81 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 728 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 97 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 217 | 0.040 |
Why?
|
| Gangliosides | 1 | 1999 | 5 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 24 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 76 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1999 | 9 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 429 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 37 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2001 | 222 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 101 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2019 | 124 | 0.040 |
Why?
|
| Probability | 2 | 2010 | 159 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 140 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 187 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2011 | 175 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 148 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 240 | 0.040 |
Why?
|
| Aristolochic Acids | 1 | 2017 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 2017 | 20 | 0.040 |
Why?
|
| Epithelium | 1 | 2017 | 31 | 0.040 |
Why?
|
| Lipids | 1 | 2019 | 232 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2017 | 66 | 0.040 |
Why?
|
| Leukocytes | 1 | 2017 | 57 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 220 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 167 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 547 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 468 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2017 | 37 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1428 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 27 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 367 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2017 | 108 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2016 | 2 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2016 | 4 | 0.030 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2016 | 3 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2016 | 19 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2016 | 61 | 0.030 |
Why?
|
| Denmark | 1 | 2016 | 4 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 21 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 40 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 494 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 24 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 225 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 21 | 0.030 |
Why?
|
| Testosterone | 1 | 2016 | 48 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 162 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 28 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2015 | 30 | 0.030 |
Why?
|
| Kenya | 1 | 2015 | 11 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 57 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 137 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 75 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 35 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 71 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 290 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 81 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 206 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 152 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1995 | 15 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 279 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 288 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2007 | 462 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2016 | 256 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 298 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 846 | 0.030 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2014 | 17 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 249 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 173 | 0.030 |
Why?
|
| Sutures | 1 | 2013 | 20 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 56 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 157 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 46 | 0.030 |
Why?
|
| SEER Program | 1 | 2012 | 30 | 0.030 |
Why?
|
| Urinalysis | 1 | 2012 | 27 | 0.030 |
Why?
|
| Cadaver | 1 | 2013 | 161 | 0.030 |
Why?
|
| Pelvis | 1 | 2013 | 61 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 71 | 0.030 |
Why?
|
| Cadherins | 1 | 2012 | 26 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 73 | 0.030 |
Why?
|
| Tretinoin | 1 | 2011 | 34 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1267 | 0.020 |
Why?
|
| Muscles | 1 | 2011 | 62 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 206 | 0.020 |
Why?
|
| Microtomy | 1 | 2010 | 1 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 94 | 0.020 |
Why?
|
| Selection Bias | 1 | 2010 | 13 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2011 | 53 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 199 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2010 | 22 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 159 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hematocrit | 1 | 2010 | 23 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 25 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 98 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 22 | 0.020 |
Why?
|
| American Heart Association | 1 | 2010 | 87 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Chemokine CX3CL1 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Diet Records | 1 | 2009 | 33 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Flavonoids | 1 | 2009 | 18 | 0.020 |
Why?
|
| Decision Trees | 1 | 2009 | 31 | 0.020 |
Why?
|
| Ureteral Neoplasms | 1 | 2009 | 11 | 0.020 |
Why?
|
| Kidney Pelvis | 1 | 2009 | 17 | 0.020 |
Why?
|
| Vegetables | 1 | 2009 | 35 | 0.020 |
Why?
|
| Hospitals | 1 | 2009 | 102 | 0.020 |
Why?
|
| Fruit | 1 | 2009 | 53 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2009 | 55 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 111 | 0.020 |
Why?
|
| Attitude | 1 | 2008 | 40 | 0.020 |
Why?
|
| Educational Status | 1 | 2009 | 181 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2008 | 21 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1592 | 0.020 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 15 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 14 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2007 | 33 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2010 | 673 | 0.020 |
Why?
|
| Electroporation | 1 | 2007 | 14 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 266 | 0.020 |
Why?
|
| Accreditation | 1 | 2007 | 16 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 2007 | 20 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 137 | 0.020 |
Why?
|
| Protein Binding | 1 | 2007 | 201 | 0.020 |
Why?
|
| Infant | 1 | 2010 | 1061 | 0.020 |
Why?
|
| Comet Assay | 1 | 2005 | 3 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 52 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2006 | 61 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 629 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2005 | 57 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 84 | 0.020 |
Why?
|
| Antioxidants | 1 | 2006 | 114 | 0.020 |
Why?
|
| Curriculum | 1 | 2007 | 213 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2005 | 1 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 16 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 392 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 81 | 0.020 |
Why?
|
| Radiometry | 1 | 2005 | 40 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 10 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2004 | 4 | 0.020 |
Why?
|
| Vitamin D | 1 | 2006 | 184 | 0.020 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2004 | 13 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 185 | 0.010 |
Why?
|
| Acetylation | 1 | 2003 | 14 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 40 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 32 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 99 | 0.010 |
Why?
|
| Histones | 1 | 2003 | 53 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 191 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 49 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 208 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 246 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 414 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1999 | 30 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 57 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 6 | 0.010 |
Why?
|
| Ionomycin | 1 | 1999 | 4 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 11 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 7 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 12 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1999 | 15 | 0.010 |
Why?
|
| Blood Cells | 1 | 1999 | 9 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 7 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 20 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 147 | 0.010 |
Why?
|
| Scrotum | 1 | 1995 | 7 | 0.010 |
Why?
|